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(57) ABSTRACT 
Systems and methods for isolating samples are provided. The 
system comprises a first membrane and a second membrane 
disposed within an enclosure. First and second reservoirs can 
also be disposed within the enclosure and adapted to contain 
one or more reagents therein. A first valve can be disposed 
within the enclosure and in fluid communication with the first 
reservoir, the second reservoir, or both. The first valve can 
also be in fluid communication with the first or second mem-
branes or both. The first valve can be adapted to selectively 
regulate the flow of the reagents from the first reservoir, 
through at least one of the first and second membranes, and 
into the second reservoir. 
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SYSTEM AND METHOD FOR ISOLATION OF 
SAMPLES 
ORIGIN OF THE INVENTION 
The invention described herein was made in the perfor-
mance of work under a NASA contract and is subject to the 
provisions of Section 305 of the National Aeronautics and 
Space Act of 1958, Public Law 85-568 (72 Stat. 435; 42 
U.S.C. 2457). 
BACKGROUND 
Field 
Embodiments described herein generally relate to appara-
tus, systems, and methods for isolation of samples, such as 
samples containing nucleic acid, cells, proteins, or chemical 
materials. 
SUMMARY 
This summary is provided to introduce a selection of con-
cepts that are further described below in the detailed descrip-
tion. This summary is not intended to identify key or essential 
features of the claimed subject matter, nor is it intended to be 
used as an aid in limiting the scope of the claimed subject 
matter. 
Systems and methods for isolating samples are provided. 
The system can include first and second membranes disposed 
within an enclosure. First and second reservoirs can also be 
disposed within the enclosure and adapted to contain one or 
more reagents therein. A first valve can be disposed within the 
enclosure and in fluid communication with the first reservoir, 
the second reservoir, or both. The first valve can also be in 
fluid communication with the first membrane, the second 
membrane, or both. The first valve can be adapted to selec-
tively regulate the flow of the reagents from the first reservoir, 
through at least one of the first and second membranes, and 
into the second reservoir. A second valve can be disposed 
within the enclosure and in fluid communication with the first 
reservoir, the second reservoir, or both. The second valve can 
also be in fluid communication with the first membrane, the 
second membrane, or both. The second valve can be adapted 
to selectively regulate the flow of the reagents from the first 
reservoir, through at least one of the first and second mem-
branes, and into the second reservoir. 
The method includes flowing a first reagent from a first 
reservoir through a first membrane and a first valve and into a 
second reservoir containing a second reagent to form a first 
mixture including the first and second reagents. The first 
mixture then flows through the first valve, a second valve, and 
a second membrane and into a third reservoir. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts a cross-sectional view of an illustrative 
sample isolation system, according to one or more embodi-
ments described. 
FIG. 2 depicts a partial close-up view of the sample isola-
tion system depicted in FIG. 1, according to one or more 
embodiments described. 
FIG. 3 depicts a cross-sectional view of an illustrative 
injector that can be integrated or coupled to one or more 
components of the sample isolation system, according to one 
or more embodiments described. 
2 
FIGS. 4A-E depict cross-sectional views of the sample 
isolation system during a DNA isolation process, according 
to one or more embodiments described. 
FIG. 5 depicts an illustrative system for operating one or 
5 more sample isolation systems at the same or substantially the 
same time, according to one or more embodiments described. 
FIG. 6 depicts an elevational view of an illustrative sample 
isolation housing depicted in FIG. 5, according to one or more 
embodiments described. 
10 	 FIG. 7 depicts a cross-sectional view of another illustrative 
actuator, according to one or more embodiments described. 
FIG. 8 depicts an illustrative valve coupling disposed 
proximate a valve of the sample isolation system, according 
to one or more embodiments described. 
15 
DETAILED DESCRIPTION 
FIG. 1 depicts a cross-sectional view of an illustrative 
sample isolation system or enclosure 100, and FIG. 2 depicts 
20 a partial close-up view of the sample isolation system 100 
depicted in FIG. 1. The isolation system 100 is a pipette-free, 
closed or self-contained system. As a closed or self-contained 
system, fluid disposed within the system 100 does not escape 
or leak out, as would occur with traditional open-ended 
25 pipettes. Given that the system is self-contained, it may be 
used in environments in which it is desirable to minimize the 
escape of samples or the exposure to contaminants. One 
example of such environment is a microgravity environment, 
such as the International Space Station. Another example 
30 might be a terrestrial environment such as a clean room or a 
laboratory for biosafety. 
Two or more membrane support assemblies 103, 106 can 
be contained or encapsulated within the isolation system 100. 
Each support assembly 103, 106 can include one or more 
35 support members 260, 270 for holding or supporting a mem-
brane 263, 273. In at least one embodiment, the support 
members 260, 270 can be perforated and disposed adjacent 
opposing surfaces of the membranes 263, 273 such that the 
membranes 263, 273 are disposed within the support mem- 
4o bers 260, 270. The term "membrane," as used herein, refers to 
any material or layers of material that act as a selective barrier, 
allowing selected fluids and/or particles to pass therethrough, 
or in other embodiments allowing items of interest, such as 
proteins, molecules, cells, or particles, to be instead retained 
45 therein. As such, fluid and/or particles can flow or pass 
through the support members 260, 270 and the membranes 
263, 273 while other items of interest bind to the membranes 
263, 273. 
Suitable membranes can include one or more micropores. 
5o The micropores can have an average pore diameter ranging 
from a low of about 0.2 µm, about 0.4 µm, or about 0.6 µm to 
a high of about 1 µm, about 2 µm, about 3 µm, about 4 µm, or 
about 5 µm, such as a membrane suitable for RNA/DNA 
isolation. However, for other applications, the micropores can 
55 have an average pore diameter ranging from a low of about 
0.0001 µm, about 0.001 µm, or about 0.01 µm to a high of 
about 0.05 µm, about 0.1 µm, or about 0.2 µm (e.g., forprotein 
isolation or separation), or from a low of about 10 µm, about 
20 µm, or about 30 µm to a high of about 50 µm, about 75 µm, 
60 or about 100 µm (e.g., for filtering single cell suspension). 
The membranes can also be used for binding, isolating, and 
separating specific molecules and particles, isolating specific 
types of cells, and reagent sterilization. 
In one embodiment, a sample of interest, such as blood, 
65 saliva, urine, buffy coat, bacterial cultures, and the like con- 
taining nucleic acid, can be placed on the "first' or "sample" 
membrane 263. In at least one embodiment, the sample can be 
US 8,669,096 B2 
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placed directly on the first membrane 263, and the first mem-
brane 263 can then be placed within a support member 260 of 
the support assembly 103. The support assembly 103 can then 
be disposed within the isolation system 100. 
The first membrane 263 and/or the "second" or "binding" 
membrane 273 can be, but are not limited to, a proteinase 
membrane, a homogenizing membrane, a filtering mem-
brane, a binding membrane, or any combination thereof. For 
example, the first membrane 263 can be a proteinase mem-
brane containing the sample, and the second membrane 273 
can be a binding membrane that acts as a platform or surface 
to bind precipitated nucleic acids released from the first mem-
brane 263, while not absorbing potentially contaminating 
proteins or other biologic agents. Suitable commercially 
available membranes can include, but are not limited to, 
membranes found in standard kits for the purification of DNA 
or RNA sold commercially by the manufacturer Qiagen (e.g., 
DNeasy® Blood and Tissue Kit, RNeasy® Mini Kit, RNe-
asy® Protect Mini Kit, and RNeasy(k Plant Mini Kit). 
Suitable membranes 263, 273 can also include a solid 
surface functionalized with immobilized active enzymes and 
high density enzyme surfaces. More specifically, membranes 
for use with the present sample isolation system 100 can 
include a solid surface functionalized with immobilized pro-
teinase, such as trypsin, chymotrypsin, endoproteinase G1uC, 
papain, endoproteinase pepsin, proteinase K, and the like. 
Suitable solid surfaces can also include glass fiber, glass fiber 
treated with oleophobic coatings, silica particles or beads, 
silica particles or beads coated with oleophobic coatings, 
nylon, and other oleophobic materials, and the like. For 
example, suitable membranes can include the DigesTipTM 
produced by the manufacturer ProteoGen Bio in Siena, Italy. 
In at least one embodiment, the surface can be coated with 
complementary oligo nucleictides, antibodies, covalently or 
non-covalently binding to target molecules, and/or any par-
ticles and membranes used for separating molecules based on 
size and isoelectric point. 
One or more valves (two are shown in FIGS. 1 and 2 as 
parts 109, 110) and one or more injectors (six are shown in 
FIGS. 1 and 2 as parts 151, 152, 153, 171, 172, 173) can also 
be located within the sample isolation system 100. In at least 
one embodiment, the membrane support assemblies 103, 
106, the valves 109,110, and the injectors 151, 152, 153, 171, 
172, 173 can be coupled together to form the enclosed isola-
tion system 100. The components may be coupled in any 
manner known in the art to form an air-tight enclosure for use 
in closed or self-contained environments. For example, the 
components can be threaded together. In at least one embodi-
ment, tubing (not shown) having a diameter similar to the 
diameter of the flow path through the valves 109, 110 (e.g., 
15-gauge tubing) canbe coupled to and disposed between the 
injectors 151, 152, 153, 171, 172, 173 and the valves 109,110 
to provide more flexibility to the sample isolation system 100. 
The first membrane support assembly 103 can be thread-
ably engaged or otherwise operatively connected in a manner 
so as to prevent leaks of fluid or particles between the first 
injector 151 and the first valve 109. The second membrane 
support assembly 106 can be threadably engaged or other-
wise operatively connected in a manner to prevent leaks of 
fluid or particles between the first valve 109 and the second 
valve 110. The second and third injectors 152, 153, respec-
tively can be threadably engaged or otherwise operatively 
connected in a sealed manner with the first valve 109. The 
fourth, fifth, and sixth injectors 171, 172, 173, respectively, 
can be threadably engaged or otherwise operatively con-
nected in a sealed manner with the second valve 110. As may 
be appreciated by the skilled artisan having the benefit of the 
description contained herein, the components may be 
coupled together in any other suitable configuration, and any 
number of valves and/or injectors can be used. 
In one embodiment, the valves 109, 110 each include a 
5 rotatable housing having at least one bore (two are shown in 
FIGS. 1 and 2 such that the valves are four-way valves) 
formed therethrough. As such, the valves 109, 110 can be 
actuated or rotated such that one or more flow paths 113,114, 
115 (as illustrated by two-way vectors) can provide fluid 
to communication from a first reservoir disposed within one 
injector (151, 152, 153, 171, 172, 173) through at least one of 
the valves (109, 110) and into a second reservoir of another 
injector (151, 152, 153, 171, 172, 173). As shown in FIG. 1, 
15 the first and second valves 109,110 are oriented such that the 
flow path 113 extends between the first injector 151 and the 
second injector 152 (through the first membrane 263), the 
flow path 114 extends between the third injector 153 and the 
fourth injector 171 (through the second membrane 273), and 
20 the flow path 115 extends between the fifth injector 172 and 
the sixth injector 173. However, as may be appreciated by the 
skilled artisan having benefit of this description, the first and 
second valves 109, 110 can be rotated to vary the flow paths 
113, 114, 115, into other flow paths as will be described in 
25 more detail below. 
The flowpaths 113,114,115 can, atleastinpart, depend on 
the type of valves 109, 110 used and/or the configuration of 
the valves 109,110 in relation to the other components of the 
sample isolation system 100. In one embodiment, suitable 
so valves 109, 110 with a rotatable housing can be or include 
valves manufactured and commercially sold by the Hamilton 
Company of Reno, Nev. Further, the flow paths 113,114,115 
can be unidirectional and/or bidirectional (as indicated by the 
two-way vectors). In one embodiment, a solution and/or 
35 reagent can be both drawn into and/or discharged from an 
injector 151, 152, 153, 171, 172, 173 or any other component 
of the sample isolation system 100, along the flow paths 113, 
114, 115. 
The valves 109, 110 can be one-way valves (e.g., check 
40 valve) and/or multi-way valves (e.g., two-way, three-way, or 
four-way valves). The valves 109, 110 can further include a 
control unit (not shown) that can selectively rotate the valves 
109, 110 to provide the desired flowpaths of interest, such as 
the flowpaths 113, 114, 115. The control unit can include, but 
45 is not limited to, a manual handle connected to the valves 109, 
110 and/or an electronic actuator. For example, a manual 
handle or switch coupled to the valves 109, 110 can be rotated 
by the user to select the desired setting of the valves 109,110 
and to selectively form the flow paths (such as 113, 114, 115) 
5o desired through the sample isolation system 100. 
The injectors 151, 152, 153, 171, 172, 173 can further 
include one or more chambers or reservoirs (six are shown as 
corresponding parts 154, 155, 156, 174, 175, 176, respec-
tively) for storing reagents or other fluids used for the sample 
55 isolation process. In at least one embodiment, a bore 101 can 
be formed through a piston 166 in the first injector 151 to 
provide a path of fluid communication through to the reser-
voir 154 of the first injector 151. In at least one embodiment, 
the sample of interest can be inserted into the system 100 via 
60 the bore 101. Further, the bore 101 and/or the reservoir 154 of 
the first injector 151 can be sonicated to mix or agitate the 
sample and/or reagent disposed therein. 
A bore 102 can also be formed through a piston 136 of the 
third injector 153 to provide a path of fluid communication 
65 through to the reservoir 156 of the third injector 153. In at 
least one embodiment, a vacuum or other device 104 can be in 
fluid communication with the bore 102 and adapted to 
US 8,669,096 B2 
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increase or decrease the pressure within the system 100. 	 pipe-threading, or other fasteners, or any combination 
Further, the vacuum 104 can be adapted to dry the first and/or 	 thereof. Coupling of the cap 363 to the body 334 can substan- 
second membranes 263, 273. 	 tially enclose or seal the one or more ends 349, 351 of the 
The reagents used within the system 100 can be or include 	 body 300. The cap 363 can also, at least in part, define the 
any fluid for molecular and/or cellular isolation techniques 5 reservoir 354 of the injector 300. 
and can be used in any amount. Such reagents can include one 	 The membrane 366 of the injector 300 can be disposed on 
or more lysing and denaturing substances and/or one or more 	 or within the injector 300 and can form a seal with the inner 
buffer solutions. In at least one embodiment, a first reagent 	 wall 346 of the body 334. For example, the membrane 366 in 
can be or include a phosphate buffer solution (PBS), a salt, a 	 FIG. 3 is disposed on the open first end 351 of the body 334, 
detergent, an alcohol, or a protease, and a second reagent can io spanning the cross-section of the inner wall 346. The mem- 
include a lysis buffer such as a solution containing guani- 	 brane 366 can be similar to the membranes 263, 273 
dinium chloride, which helps break open cells and their nuclei 
	
described above, and thus, will not be described again in 
to extract deoxyribo nucleic acid (DNA) for analysis. One 	 detail. 
example of a lysis buffer sold commercially is the product 	 The piston 343 of the injector 300 can include a plunger 
named `Buffer AL" sold by the manufacturer Qiagen. In 15 344 on one end and an integrated thumb tab 345 on the other 
another embodiment, the detergent can be a quaternary amine 	 end. As shown in FIG. 3, the plunger 344 can form a seal with 
cationic detergent such as cetyltrimethylammonium bromide 	 the inner wall 346 of the body 334. The thumb tab 345 is 
(CTAB), Guanidine thiocyanate (GuSCN), and the like, and/ 	 capable of maneuvering the piston 343 in a sliding engage- 
or the protease can be trypsin, chymotrypsin, endoproteinase 	 ment back and forth along the inner wall 346 by applying a 
G1uC, papain, endoproteinase pepsin, proteinase K, and the 20 force upon the piston 343. The force upon the piston 343 can 
like. For example, the first reagent can include from a low of 
	
be applied in a first direction toward the first end 351 or in a 
about 0.1 mL, about 0.2 mL, about 0.4 mL, about 0.6 mL, 	 second direction toward the second end 349. The force 
about 0.8 mL, or about 1.0 mL to a high of about 2.0 mL, 	 applied upon the piston 343 can be from one or more passive 
about 3.0 mL, about 4.0 mL, about 5.0 mL, or more of PBS, 	 or active sources and can be a negative pressure or positive 
an alcohol solution, a detergent solution, or a combination 25 pressure. For example, the pressure applied upon the piston 
thereof. The second reagent can include from a low of about 	 343 can be from an automated actuator, an increase or 
0.1 mL, about 0.2 mL, about 0.4 mL, about 0.6 mL, about 0.8 
	
decrease in the size of the reservoir 354 of the injector 300, an 
mL, or about 1.0 mL to a high of about 2.0 mL, about 3.0 mL, 	 applied pressure on the thumb tab 345, an applied pressure 
about 4.0 mL, about 5.0 mL, or more of a lysis buffer. 	 from the plunger 344, or any combination thereof. 
In another embodiment, the first reagent can include a lysis 30 	 A bore 356 can extend through the piston 343 and be in 
buffer, and the second reagent can include an alcohol solu- 	 fluid communication with the reservoir 354. The bore 356 can 
tion. The first reagent can include from a low of about 0.1 mL, 	 be sealed with a plug or sealing member 373, or by other 
about 0.2 mL, about 0.4 mL, about 0.6 mL, about 0.8 mL, or 	 devices, such as a quick-connect coupler, a pierceable self- 
about 1.0 mL to a high of about 2.0 mL, about 3.0 mL, about 	 resealable elastic stopper (e.g. rubber septum), or any com- 
4.0 mL, about 5.0 mL, or more of the lysis buffer. The second 35 bination thereof. The bore 356 can include a vacuum line 
reagent can include from a low of about 0.1 mL, about 0.2 mL, 	 connection, a sonicator, a homogenizer, or the like coupled to 
about 0.4 mL, about 0.6 mL, about 0.8 mL, or about 1.0 mL 	 or in fluid communication therewith. The vacuum can be 
to a high of about 2.0 mL, about 3.0 mL, about 4.0 mL, about 	 adapted to vary the pressure within the system 100 and/or dry 
5.0 mL, or more of the alcohol solution. The alcohol solution 	 the membrane 366. 
can contain from a low of about 50%, about 60%, or about 40 In at least one embodiment, the bore 356 can be used to 
70% to a high of about 80%, about 90%, or about 95% 
	
introduce the biological sample to the system 100. In another 
ethanol. 	 embodiment, the reservoir 354 can include a first reagent, the 
FIG. 3 depicts a cross-sectional view of an illustrative 	 bore 356 can include a second reagent, and an additional 
injector 300 that can be integrated or coupled to one or more 	 membrane (not shown) can be positioned between the bore 
components of the sample isolation system 100, according to 45 356 and the reservoir 354 in the general vicinity of the plunger 
one or more embodiments. The injector 300 can be designed 	 344. 
for handling biological samples, and it can be assembled 
	
In at least one embodiment, the injector 300 (or any injec- 
anywhere within the system 100. The injector 300 can be 	 tor in the system 100) can include a heater, a micro-magnet, 
similar to the injectors 151, 152, 153, 171, 172, 173 shown 	 and/or an interface that can receive a spectrophotometer. The 
and described above. For example, the injector 300 can 50 end of the plunger 344 can be the platform for array analysis, 
include a body 334 having a first end 351 and a second end 
	
including, but not limited to, anchoring complementary 
349. The body 334 can include an inner surface 346 that 	 cDNAs, antibodies, or other molecules, which specifically 
defines a bore or passageway completely or at least partially 	 recognize target molecules. 
therethrough. A piston 343 can be disposed within at least a 	 FIGS. 4A-E depict cross-sectional views of the sample 
portion of the bore. A reservoir 354 can be formed between 55 isolation system 100 during an exemplary isolation process, 
the piston 343 and the first end 351 of the body 334. 	 according to one or more embodiments. Referring now to 
The injector 300 can further include one or more caps (one 	 FIGS. 1 and 4A-E, in operation, the sample, such as a blood 
is shown in FIG. 3 as 363), one or more membranes (one is 	 sample containing nucleic acids, can be placed on the first 
shown as 366), one or more unitized finger grips (one is 	 membrane 263 of the membrane support assembly 103. The 
shown as 337), and one or more couplers (one is shown as 60 membrane support assembly 103 can then be disposed within 
361). The cap 363 of the injector 300 canbe coupled to one or 	 the sample isolation system 100. The first valve 109 can be 
more ends 349, 351 of the body 334 of the injector 300. FIG. 	 selectively rotated to provide a first flow path 113 (see FIG. 1) 
3 illustrates the cap 363 coupled to the open first end 351 of 
	
between the first injector 151 and the second injector 152 
the body 334 throughthe coupler 360. The cap 363 can also be 	 through the first valve 109 and the first membrane 263. 
coupled to the body 334 through any appropriate means pre-  65 	 The first reservoir 154 can have the first reagent disposed 
viously discussed including, but not limited to, one or more 	 therein, and the second reservoir 155 can have the second 
clamps, straps, latches, snap-fit mechanisms, pipe-fittings, 	 reagent disposed therein. The piston 166 of the first injector 
US 8,669,096 B2 
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151 can be moved to decrease the volume of the first reservoir 
154, thereby forcing the first reagent through the first flow 
path 113 and into the second reservoir 155 of the second 
injector 152. Thus, the first reagent can flow through the first 
valve 109 and first membrane 263 before entering the second 
reservoir 155 of the second injector 152. When the first 
reagent contacts the first membrane 263, the cells can be 
disrupted and the nucleic acids can be released. Accordingly, 
the first reagent and the released nucleic acids can be com-
bined with the second reagent in the second reservoir 155 to 
form a first mixture. 
The piston 186 of the second injector 152 can subsequently 
be moved to decrease the volume of the second reservoir 155, 
thereby forcing the first mixture through the first flow path 
113 and back into the first reservoir 154. This process can be 
subsequently repeated one or more times to ensure complete 
mixture of the first and second reagents and to ensure a 
complete interaction between the first mixture with the first 
membrane 263. Once mixing is complete, the first mixture 
can then be forced back into the reservoir 154 of the first 
injector 151. 
The first valve 109 can be then be selectively rotated to 
provide a second flow path 116 (see FIG. 4A) between the 
first reservoir 154 and the third reservoir 156 through the first 
valve 109 and the first membrane 263. The reservoir 156 of 
the third injector 153 can include a third reagent. In at least 
one embodiment, the third reagent can include an ethanol 
solution. For example, the reservoir 156 of the third injector 
153 can include from a low of about 0.1 mL, about 0.2 mL, 
about 0.4 mL, about 0.6 mL, about 0.8 mL, or about 1.0 mL 
to a high of about 2.0 mL, about 3.0 mL, about 4.0 mL, about 
5.0 mL, or more of the solution. The solution can contain from 
a low of about 50%, about 60%, or about 70% to a high of 
about 80%, about 90%, or about 95% ethanol. The piston 166 
of the first injector 151 can then be moved to decrease the 
volume of the first reservoir 154, thereby forcing the first 
mixture through the second flow path 116 and into the third 
reservoir 156 of the third injector 153. Thus, the first mixture 
can flow through the first valve 109 and first membrane 263 
before entering the third reservoir 156 of the third injector 
153, thereby combining the first mixture and the third reagent 
to form a second mixture. The piston 136 of the third injector 
153 can then be moved to decrease the volume of the third 
reservoir 156, thereby forcing the second mixture through the 
second flow path 116 and back into the first reservoir 154 of 
the first injector 151. This process can be repeated one or 
more times. The second mixture can then be forced back into 
the third injector 153. 
The first and second valves 109, 110 can be then be selec-
tively rotated to provide a third flow path 117 (see FIG. 413) 
between the third reservoir 156 and the fourth reservoir 174 
through the first and second valves 109, 110 and the second 
membrane 273. The reservoir 174 of the fourth injector 171 
can define an empty volume. The piston 166 of the third 
injector 153 can then be moved to decrease the volume of the 
third reservoir 156, thereby forcing the second mixture 
through the third flow path 117 (including the second mem-
brane 273) and into the reservoir 174 of the fourth injector 
171. The flow of the second mixture through the second 
membrane 273 can effectively bind the released nucleic acids 
in the second mixture on the second membrane 273. The 
binding of the nucleic acids on the second membrane 273 can 
separate the nucleic acids from one or more contaminants 
contained in the second mixture. Thus, one or more contami-
nants of the second mixture can be contained in the reservoir 
174 of the fourth injector 171. 
8 
The first and second valves 109,110 can then be selectively 
rotated to provide a fourth flow path 118 (see FIG. 4C) 
between the fifth reservoir 175 and one of the second and third 
reservoirs 155,156 (respectively) through the first valve 109, 
5 the secondmembrane 273, andthe secondvalve 110. The fifth 
reservoir 175 of the fifth injector 172 can include one or more 
fourth reagents. In at least one embodiment, the fourth 
reagent can include a wash buffer solution. For example, the 
fifth injector 172 can include from a low of about 0.1 mL, 
io about 0.2 mL, about 0.4 mL, about 0.6 mL, about 0.8 mL, or 
about 1.0 mL to a high of about 2.0 mL, about 3.0 mL, about 
4.0 mL, about 5.0 mL, or more of the solution. The piston 126 
of the fifth injector 172 can then be moved to decrease the 
volume of the fifth reservoir 175, thereby forcing the wash 
15 buffer through the fourth flow path 118 and into, for example, 
the third reservoir 156 of the third injector 153. Thus, the 
wash buffer can flow through the second valve 110, the sec-
ond membrane 273, and the first valve 109 before entering the 
third reservoir 156 of the third injector 153. 
20 	 The wash buffer can serve to gently separate protein, lipids, 
and cell debris from the nucleic acids (DNA) bound to the 
second membrane 273. The wash buffer can be a high or low 
salt wash buffer. The wash buffer can include a buffering 
agent, containing Guanidine thiocyanate (GuSCN)/Guani- 
25 dine hydrochloride (Gu-HCl), salt, 20 mM Tris-HCl, EDTA, 
and/or alcohol. In at least one embodiment, the salt can be 
from about 10 mM to about 100 mM NaCl or the like, and the 
buffering agent can be about 20 mM Tris-HCl. 
The sample isolation system 100 can further provide an 
3o additional wash buffer to further separate the residual cell 
debris from the nucleic acids (DNA) on the second membrane 
273. For example, the sixth injector 173 can include from a 
low of about 0.1 mL, about 0.2 mL, about 0.4 mL, about 0.6 
mL, about 0.8 mL, or about 1.0 mL to a high of about 2.0 mL, 
35 about 3.0 mL, about 4.0 mL, about 5.0 mL, or more of the 
additional wash buffer. The additional wash buffer can con-
tain ethanol. 
To provide the additional washbuffer, the second valve 110 
can be selectively rotated to provide a fifth flow path 119 (see 
4o FIG. 4D) between the sixth reservoir 176 and the fifth reser-
voir 175 through the second valve 110. The piston 196 of the 
sixth injector 173 can then be moved to decrease the volume 
of the sixth reservoir 176, thereby forcing the second wash 
buffer through the fifth flow path 119 and into the reservoir 
45 175 of the fifth injector 172. 
The first and second valves 109,110 can then be selectively 
rotated to provide a sixth flow path 120 (see FIG. 4E) between 
the fifth reservoir 175 and the reservoir 155,156 of the second 
or third injectors 152, 153, respectively. For example, the 
50 sixth flow path 120 can flow into the reservoir 156 of the third 
injector 153. The piston 126 of the fifth injector 172 can then 
be moved to decrease the volume of the fifth reservoir 175, 
thereby forcing the second wash buffer through the sixth flow 
path 120 and into the reservoir 156 of the third injector 153. 
55 The second membrane 273 can now contain the nucleic 
acids (DNA) released from the first membrane 263. The 
membrane 273 can be either air-dried, or the vacuum 104 can 
then be coupled to the third injector 153 and in fluid commu-
nication with the second membrane 273 via the bore 102, the 
6o reservoir 156, and the valve 109. The vacuum 104 can be 
adapted to remove the reagents disposed within the third 
reservoir 156 and/or dry the second membrane 273. The 
second membrane 273 can then be removed and used for 
subsequent processes, such as a polymerase chain reaction 
65 (PCR) process. 
FIG. 5 depicts an elevational view of an illustrative system 
500 for operating one or more sample isolation systems 100 
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simultaneously, according to one or more embodiments. The 
system 500 can include a plurality of sample isolation hous-
ings (four are shown in FIG. 5 as 502, 504, 506, 508), each 
adapted to have a sample isolation system 100 disposed 
therein. One or more actuators (one is shown as 510) can also 
be coupled to the system 500; however, for purposes of clar-
ity, the actuator 510 is shown separately. Each actuator 510 
can include a piston 512 and a plurality of contacts 514, 516, 
518, 520. When the piston 512 is pressed, the contacts 514, 
516, 518, 520 can move forward and apply a force on, for 
example, the piston 166 of four first injectors 151 in four 
different sample isolation systems 100 simultaneously. 
FIG. 6 depicts an elevational view of the illustrative sample 
isolation housing 502 depicted in FIG. 5, according to one or 
more embodiments. The sample isolation system 100 can be 
disposed within the housing 502. The housing 502 can 
include one or more extension members (five are shown in 
FIG. 6 as 602, 604, 606, 608, 610) and one or more valve 
couplings (two are shown as 612, 614). As shown in the 
embodiment of FIG. 6, each extension member 602, 604, 606, 
608, 610 is disposed between a piston 166, 186, 136, 196, 126 
(respectively) of an injector 151, 152, 153, 173,172 (respec-
tively). The extension members 602, 604, 606, 608, 610 
operatively connect to the actuator 510 at one of the contacts 
514, 516, 518, 520. By way of example, when the actuator 
510 moves forward, the contact 514 (if so operatively con-
nected thereon) can move an extension member 602 forward, 
which in turn, moves the piston 166 of the first injector 151 of 
the sample isolation system 100. Thus, as the actuator 510 
moves forward, the associated multiple contacts (such as 514, 
516, 518, 520 of FIG. 5) can move the correspondingly con-
nected extension members (such as one of 602, 604, 606, 608, 
610) in multiple sample isolation housings. In a similar way, 
the valve couplings 612, 614 can be adapted to actuate the 
valves 109, 110 of multiple sample isolation systems 100 
simultaneously. 
FIG. 7 depicts a cross-sectional view of another illustrative 
actuator 700, according to one or more embodiments. The 
actuator 700 can include a piston 702 and a plurality of 
contacts 704. For example, the contacts 704 can be male luer 
locks. When the piston 702 is pressed, the contacts 704 can 
move forward and apply a force on, for example, multiple 
extension members (602, 604, 606, 608, 610) and/or multiple 
pistons (126, 136, 146, 166, 186, 196). 
In at least one embodiment, a bore 706 can be formed 
through the piston 702 providing a flow path therethrough. A 
vacuum (similar to vacuum 104 of FIG. 1) can be coupled to 
the piston 702 and adapted to dry the membrane 273 via the 
flowpath through the bore 706 and the contacts 704. 
FIG. 8 depicts an illustrative valve coupling 800 disposed 
adjacent a valve 820 of the sample isolation system 100, 
according to one or more embodiments. The valve 820 can be 
similar to the valves 109, 110 of FIG. 1. In at least one 
embodiment, the valve coupling 800 and the valve 820 can 
interact via a male-female connection. For example, the valve 
820 can include a first surface 822 and a second surface 824 
having one or more protrusions 826, 828 extending there-
from. The valve coupling 800 can include first and second 
surfaces 802, 804, each including a recess (only one is shown 
in FIG. 8 as 806) extending into the valve coupling 800. As 
such, the protrusion 828 on the valve 820 can fit within the 
recessed space 806, in the valve coupling 800 so that when the 
valve coupling 800 is turned, the valve 820 turns as well. As 
may be appreciated by a skilled artisan having the benefit of 
the description contained herein, a valve coupling 800 can be 
disposed between any two valves 800 in the system 500 so 
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that a plurality of valves 800 in multiple, adjacent sample 
isolation systems 100 can be turned simultaneously. 
Various terms have been defined above. To the extent a 
term used in a claim is not defined above, it should be given 
5 the broadest definition persons in the pertinent art have given 
that term as reflected in at least one printed publication or 
issued patent. Furthermore, all patents, test procedures, and 
other documents cited in this application are fully incorpo-
rated by reference to the extent such disclosure is not incon- 
io sistent with this application and for all jurisdictions in which 
such incorporation is permitted. 
Although only a few exemplary embodiments have been 
described in detail above, those skilled in the art will readily 
appreciate that many modifications are possible in the exem- 
15 plary embodiments without materially departing from the 
novel teachings and advantages of this invention. Accord-
ingly, all such modifications are intended to be included 
within the scope of this invention as defined in the following 
claims. In the claims, means-plus-function and step-plus- 
20 function clauses are intended to cover the structures or acts 
described herein as performing the recited function and not 
only structural equivalents, but also equivalent structures. 
Thus, although a nail and a screw may not be structural 
equivalents in that a nail employs a cylindrical surface to 
25 secure wooden parts together, whereas a screw employs a 
helical surface, in the environment of fastening wooden parts, 
a nail and a screw may be equivalent structures. 
What is claimed is: 
1. A sample isolation system, comprising: 
so 	 an air-tight enclosure; 
first and second membranes disposed within the enclosure; 
first, second, third and fourth reservoirs disposed within 
the enclosure, wherein each reservoir is adapted to con- 
tain one or more reagents therein; 
35 	 a first multi-way valve disposedwithin the enclosure and in 
fluid communication with the first or second or third 
reservoirs, and in fluid communication with the first or 
second membranes or both, wherein the first multi-way 
valve is configured for providing a first bidirectional 
40 flowpath between the first reservoir and the second res-
ervoir and for providing a second bidirectional flowpath 
between the first reservoir and the third reservoir, 
wherein the first multi-way valve is adapted to selec-
tively regulate flow of one or more reagents from the first 
45 	 reservoir, through at least one of the first and second 
membranes, and into the second reservoir; and 
a second valve disposed within the enclosure and in fluid 
communication with the third and fourth reservoirs and 
the first multi-way valve, and in fluid communication 
50 with the first or second membranes or both, wherein the 
second valve is adapted to selectively regulate flow of 
one or more reagents from the third reservoir, through at 
least one of the first and second membranes, and into the 
fourth reservoir. 
55 	 2. The sample isolation system of claim 1, wherein the first 
membrane comprises a proteinase membrane. 
3. The sample isolation system of claim 1, wherein the 
second membrane comprises a binding membrane. 
4. The sample isolation system of claim 1, wherein the first 
60 membrane is disposed between the first reservoir and the first 
valve. 
5. The sample isolation device of claim 1, wherein the 
second membrane is disposed between the first and second 
valves. 
65 	 6. The sample isolation device of claim 1, wherein the first 
membrane is disposed within a first membrane support 
assembly, and the second membrane is disposed within a 
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second membrane support assembly, and wherein the first 
valve is threadably engaged to the first and second membrane 
support assemblies. 
7. The sample isolation system of claim 1, further compris-
ing a reagent disposed within the first reservoir, wherein the 
reagent is selected from the group comprising a phosphate 
buffer solution, a salt, a detergent, an alcohol, a protease, a 
lysis buffer, or a combination thereof. 
8. The sample isolation system of claim 1, further compris-
ing a reagent disposed within the second reservoir, wherein 
the reagent comprises at least one of a lysis buffer and an 
alcohol solution. 
9. The sample isolation device of claim 1, wherein the first 
and second valves each comprise a rotatable housing having 
at least one bore disposed therethrough. 
10. A method of isolating nucleic acids from a sample, 
comprising: 
placing the sample into the sample isolation system of 
claim 1; 
flowing a first reagent from a first reservoir through a first 
membrane and a first valve and into a second reservoir 
containing a second reagent to form a first mixture 
including the first and second reagents; and 
flowing the first mixture through the first valve, a second 
valve, and a second membrane and into a third reservoir. 
11. The method of claim 10, further comprising rotating the 
first valve prior to flowing the first mixture into the third 
reservoir. 
12. The method of claim 10, wherein flowing the first 
reagent through the first membrane further comprises releas-
ing nucleic acids from the first membrane such that the 
nucleic acids become disposed within the first mixture. 
13. The method of claim 12, wherein flowing the first 
mixture through the second membrane further comprises 
binding at least a portion of the nucleic acids disposed within 
the first mixture to the second membrane. 
14. The method of claim 13, further comprising flowing a 
wash buffer solution through the second membrane. 
15. The method of claim 14, further comprising drying the 
second membrane with a vacuum. 
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16. A sample isolation system, comprising: 
an air-tight enclosure; 
first and second membranes disposed within the air-tight 
enclosure; 
5 	 a first injector comprising a first reservoir; 
• second injector comprising a second reservoir; 
• third injector comprising a third reservoir; 
• fourth injector comprising a fourth reservoir; 
• fifth injector comprising a fifth reservoir; 
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wherein the first, second, third, fourth, and fifth reservoirs 
are disposed within the enclosure, and wherein each 
reservoir is adapted to contain one or more reagents 
therein; 
• first multi-way valve disposed within the enclosure and 
positioned in fluid communication with the first reser- 
15 voir and the second reservoir and the third reservoir and 
the fourth reservoir and in fluid communication with the 
first membrane and the second membrane, wherein the 
first multi-way valve is configured for providing a first 
bidirectional flowpath between the first reservoir and the 
20 second reservoir and for providing a second bidirec-
tional flowpath between the first reservoir and the third 
reservoir, wherein the first multi-way valve is adapted to 
selectively regulate flow of one or more reagents from 
the first reservoir, through at least one of the first and 
25 	 second membranes, and into the second reservoir; and 
• second multi-way valve disposed within the enclosure 
and positioned in fluid communication with the third 
reservoir and the fourth reservoir and the fifth reservoir 
and in fluid communication with the first multi-way 
30 valve and the second membrane, wherein the second 
multi-way valve is configured for providing a third bidi-
rectional flowpath between the third reservoir and the 
fourth reservoir and for providing a fourth bidirectional 
flowpath between the fourth reservoir and the fifth res- 
35 ervoir, wherein the second multi-way valve is adapted to 
selectively regulate flow of one or more reagents from 
the third reservoir, through at least one of the first multi-
way valve and the second membrane, and into the fourth 
reservoir. 
